Strs Ohio Makes New Investment in ICU Medical, Inc. $ICUI

Key Points

• Strs Ohio has acquired a new position in ICU Medical, Inc. valued at approximately $972,000, purchasing 7,000 shares in the 1st quarter.
• ICU Medical reported earnings of $2.10 per share, exceeding expectations, but its revenue declined by 8.0% compared to the previous year, amounting to $543.57 million.
• Analysts have shown positive sentiment towards ICU Medical, with the average rating updated to "Buy" and a consensus price target of $181.00 per share.

Strs Ohio purchased a new stake in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,000 shares of the medical instruments supplier's stock, valued at approximately $972,000.

Other institutional investors have also modified their holdings of the company. GAMMA Investing LLC increased its holdings in shares of ICU Medical by 27.2% during the 1st quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock valued at $99,000 after purchasing an additional 153 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of ICU Medical during the 1st quarter valued at about $859,000. Vontobel Holding Ltd. purchased a new position in shares of ICU Medical in the 1st quarter valued at about $235,000. EP Wealth Advisors LLC purchased a new stake in shares of ICU Medical in the first quarter valued at approximately $479,000. Finally, Envestnet Asset Management Inc. raised its stake in shares of ICU Medical by 8.2% during the 1st quarter. Envestnet Asset Management Inc. now owns 20,269 shares of the medical instruments supplier's stock worth $2,815,000 after buying an additional 1,534 shares during the period. Hedge funds and other institutional investors own 96.10% of the company's stock.

Insider Buying and Selling

In related news, Director David C. Greenberg acquired 1,200 shares of the firm's stock in a transaction dated Wednesday, August 27th. The shares were purchased at an average cost of $126.42 per share, for a total transaction of $151,704.00. Following the acquisition, the director owned 7,960 shares in the company, valued at $1,006,303.20. The trade was a 17.75% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Vivek Jain bought 21,929 shares of the business's stock in a transaction on Thursday, August 14th. The stock was purchased at an average cost of $112.84 per share, for a total transaction of $2,474,468.36. Following the transaction, the chief executive officer owned 130,149 shares of the company's stock, valued at $14,686,013.16. This trade represents a 20.26% increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

ICUI has been the subject of a number of research reports. Raymond James Financial cut their target price on shares of ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating for the company in a research note on Friday, August 8th. Wall Street Zen upgraded ICU Medical from a "hold" rating to a "buy" rating in a research report on Friday, September 5th. Finally, Piper Sandler increased their price objective on ICU Medical from $145.00 to $153.00 and gave the company an "overweight" rating in a research note on Wednesday, September 10th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $181.00.

ICU Medical Trading Up 0.1%

ICUI traded up $0.16 during trading hours on Monday, reaching $131.87. The company's stock had a trading volume of 217,741 shares, compared to its average volume of 277,111. The stock has a market cap of $3.26 billion, a PE ratio of -86.76 and a beta of 0.86. ICU Medical, Inc. has a fifty-two week low of $107.00 and a fifty-two week high of $196.26. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.44 and a quick ratio of 1.17. The business's 50-day moving average is $126.02 and its 200-day moving average is $133.13.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 EPS for the quarter, beating analysts' consensus estimates of $1.44 by $0.66. The company had revenue of $543.57 million for the quarter, compared to the consensus estimate of $543.33 million. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.The company's revenue for the quarter was down 8.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.56 earnings per share. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. As a group, equities research analysts predict that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.